Monsanto Company

Monsanto Company

Monsanto Company was originally founded in 1901 as a chemical manufacturer, but its modern form as a venture investment vehicle emerged after Bayer AG acquired the parent in 2018. The firm operates out of St. Louis, Missouri, with satellite offices in Cambridge, Boston, Somerville, Baltimore, Stamford, New York, Rahway, and Wayne. Its wealth originates from decades of agricultural chemical and biotechnology revenue, though the exact family office structure remains undisclosed. The firm targets early-stage agtech investments across seeds, traits, crop protection chemicals, and digital farming platforms. It has deployed capital into companies such as Pairwise (gene editing for crops, per AgFunder, 2022) and AgBiome (microbial crop solutions, per the firm, 2019). Geographically, the firm focuses on North America and Europe, with select deals in Latin America and Asia. Investment structures include direct equity, convertible notes, and strategic partnerships. Team size and AUM are not publicly reported. The firm maintains a network of research collaborations with universities and national labs, leveraging the legacy Monsanto R&D pipeline for deal sourcing. No notable recent operational events have been publicly reported in the last 24 months. Adjacent structures may include the Monsanto Fund, a philanthropic foundation focused on rural communities. The firm's structural differentiator is its deep integration with Bayer's agricultural science ecosystem, providing portfolio companies access to proprietary germplasm libraries, regulatory expertise, and global distribution. This hybrid model — combining corporate venture capital with a family-office-style evergreen mandate — is rare in agtech investing.